Platelet-to-lymphocyte ratio and CA19-9 are simple and informative prognostic factors in patients with resected pancreatic cancer
被引量：4
Platelet-to-lymphocyte ratio and CA19-9 are simple and informative prognostic factors in patients with resected pancreatic cancer
摘要
We read with great interest the paper “Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic factor in patients with resected pancreatic cancer” published in Hepatobiliary & Pancreatic Diseases International [1].
参考文献3
-
1Jae Min Lee,Hong Sik Lee,Jong Jin Hyun,Hyuk Soon Choi,Eun Sun Kim,Bora Keum,Yeon Seok Seo,Yoon Tae Jeen,Hoon Jai Chun,Soon Ho Um,Chang Duck Kim.Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib[J].World Journal of Gastrointestinal Oncology,2016,8(7):555-562. 被引量：12
-
2Teruhisa Sakamoto,Hiroaki Saito,Masataka Amisaki,Naruo Tokuyasu,Soichiro Honjo,Yoshiyuki Fujiwara.Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19–9 level as a prognostic factor in patients with resected pancreatic cancer[J].Hepatobiliary & Pancreatic Diseases International,2019,18(3):278-284. 被引量：3
-
3Ionut Negoi,Sorin Hostiuc,Alexandru Runcanu,Ruxandra Irina Negoi,Mircea Beuran.Superior mesenteric artery first approach versus standard pancreaticoduodenectomy： a systematic review and meta-analysis[J].Hepatobiliary & Pancreatic Diseases International,2017,16(2):127-138. 被引量：12
二级参考文献35
-
1Imran Bhatti,Oliver Peacock,Gareth Lloyd,Michael Larvin,Richard I. Hall.Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio[J].The American Journal of Surgery.2010(2)
-
2Sergei I. Grivennikov,Florian R. Greten,Michael Karin.Immunity, Inflammation, and Cancer[J].Cell.2010(6)
-
3Giovanni Germano,Paola Allavena,Alberto Mantovani.Cytokines as a key component of cancer-related inflammation[J].Cytokine.2008(3)
-
4Rebecca L. Siegel,Kimberly D. Miller,Ahmedin Jemal.Cancer statistics, 2015[J]. CA: A Cancer Journal for Clinicians . 2015 (1)
-
5H. L. Martin,K. Ohara,A. Kiberu,T. Van Hagen,A. Davidson,M. A. Khattak.Prognostic value of systemic inflammation‐based markers in advanced pancreatic cancer[J]. Intern Med J . 2014 (7)
-
6Alberto Mantovani,Paola Allavena,Antonio Sica,Frances Balkwill.Cancer-related inflammation. Nature . 2008
-
7Elinav E,Nowarski R,Thaiss C A,et al.Inflammation-induced cancer:crosstalk between tumours,immune cells and microorganisms. Nature Reviews Cancer . 2013
-
8Stotz M,Gerger A,Eisner F,et al.Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable as well as inoperable pancreatic cancer. British Journal of Cancer . 2013
-
9Aliustaoglu Mehmet,Bilici Ahmet,Seker Mesut,Dane Faysal,Gocun Murat,Konya Volkan,Ustaalioglu Bala Basak Oven,Gumus Mahmut.The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer. Hepato Gastroenterology . 2010
-
10A Sultana,C Tudur Smith,D Cunningham,N Starling,D Tait,J P Neoptolemos,P Ghaneh.Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. British Journal of Cancer . 2007
共引文献24
-
1魏玮,王艺,杨旭光.CA19-9、CEA对不同CRP水平晚期胰腺癌患者预后判断的临床价值[J].中华胰腺病杂志,2018,18(6):384-388. 被引量：15
-
2刘建辉,罗妍,陈晓,徐向升,周平.放疗前中性粒细胞/淋巴细胞 血小板/淋巴细胞 预后营养指数及CA19-9与胰腺腺癌放疗后预后关系的分析[J].中国肿瘤临床,2017,44(6):289-293. 被引量：10
-
3罗宝洋,杨勇,段云飞,察辉华,安勇,孙冬林.术前C反应蛋白和清蛋白比值对可切除胰腺癌患者预后的影响[J].中华外科杂志,2018,56(9):712-717. 被引量：15
-
4江国强,方芳.厄洛替尼联合康莱特对肺癌A549细胞增殖、侵袭及JAK2/STAT3信号通路的影响[J].郑州大学学报（医学版）,2019,54(3):418-422. 被引量：8
-
5郑楷炼,金钢.动脉入路胰十二指肠切除技术要点[J].肝胆外科杂志,2019,27(2):84-87. 被引量：6
-
6姜翀弋,王巍.“动脉先行”技术在腹腔镜胰十二指肠切除术中的应用策略[J].中华腔镜外科杂志（电子版）,2019,12(4):219-221. 被引量：4
-
7杨世伟,石军,项灿宏,曾建平,韩东冬.结肠下区动脉入路联合门静脉肠系膜上静脉切除治疗胰头癌的临床观察研究[J].中国中西医结合外科杂志,2019,25(6):925-929.
-
8赵雅文,董頔,薛茜文,张旭娟,杨艳,陈志芳.术前外周血中NLR、PLR、LMR与早期宫颈癌患者预后的相关性研究[J].新疆医科大学学报,2020,43(8):997-1003. 被引量：24
-
9张强,秦爱玉,秦玉刚.吉西他滨与厄洛替尼联合治疗胰腺癌的试验研究[J].安徽医药,2020,24(10):1952-1957. 被引量：1
-
10金晓东,应东建,曹阳.C反应蛋白/清蛋白比值对消化系统肿瘤患者预后评估价值的Meta分析[J].重庆医学,2020,49(19):3268-3273. 被引量：3
同被引文献23
-
1苏宁,郑大勇,陈斌,申鹏,罗荣城.应用组织芯片技术检测GPC3蛋白在肝细胞癌及其他肿瘤中的表达[J].广东医学,2009,30(9):1312-1314. 被引量：3
-
2张泉东,金政锡,郝迪斯.肿瘤标志物与胰腺癌相关性的研究进展[J].国际免疫学杂志,2014,37(1):57-60. 被引量：6
-
3魏玮,王艺,杨旭光.CA19-9、CEA对不同CRP水平晚期胰腺癌患者预后判断的临床价值[J].中华胰腺病杂志,2018,18(6):384-388. 被引量：15
-
4谭启泽.胰腺癌多种治疗模式的研究进展[J].中国医药指南,2016,14(9):25-26. 被引量：1
-
5张明辉,徐光如,徐金华,朱红星,徐迎春.胃癌患者术前血小板/淋巴细胞比值的预后意义[J].临床肿瘤学杂志,2016,21(10):913-918. 被引量：6
-
6敖永曦,张启洪,伍时佐,郑俏聪,李丹,吴盛,许云朋,谢小娥.CA19-9/CA50比值在不典型胰腺癌诊断及预后判断中的临床意义[J].肿瘤基础与临床,2017,30(1):42-45. 被引量：6
-
7唐雪栋,朱巍立,朱滔.NLR对卵巢癌患者预后影响的分析[J].现代实用医学,2017,29(3):295-297. 被引量：6
-
8赵忠治,王金淼,魏颖,戚峰.术前外周血NLR与PLR对胃癌预后的评估价值[J].天津医科大学学报,2018,24(1):50-54. 被引量：13
-
9路俊波.外周血内CA19-9、CA242、CEA检测对不同病理分期胰腺癌的临床诊断价值[J].现代肿瘤医学,2018,26(12):1867-1870. 被引量：13
-
10中国抗癌协会胰腺癌专业委员会,赵玉沛,虞濬.胰腺癌综合诊治指南（2018版）[J].中华外科杂志,2018,56(7):481-494. 被引量：86
引证文献4
-
1邹德泓,侯爵,常蕤,杨琴,唐世孝.血清CA19-9、CA50、PLT、PLR联合检测对胰腺导管腺癌的诊断效能[J].山东医药,2020,60(6):19-23. 被引量：3
-
2郭梁,刘海鹏,陈康,陈晓.外周血NLR和PLR对胃癌预后评估的研究进展[J].医学综述,2021,27(4):702-706. 被引量：3
-
3杨爱峰,侯鹏飞,刘伟,崔征,许鸣超,吴现磊.血清糖类抗原242水平在不同分期胰腺癌中的差异及其与患者生存期的相关性[J].实用癌症杂志,2021,36(5):803-805. 被引量：1
-
4王海静,秦芳.外周血FAR联合NLR在局部晚期或转移性胰腺癌患者预后评估中的价值[J].国际检验医学杂志,2022,43(13):1587-1592. 被引量：2
二级引证文献9
-
1邱招凤,秦江波,赵亚会,常玮,郭笑林,顾大成,陈灿月.外周血中性粒细胞与淋巴细胞比率及血小板与淋巴细胞比率对喉鳞状细胞癌预后价值的研究进展[J].中国耳鼻咽喉颅底外科杂志,2021,27(6):746-750. 被引量：2
-
2田涛,杨俊省.血清NSE、CA-50、proGRP在食管癌术后淋巴结转移中的水平变化及联合检测价值[J].国际检验医学杂志,2022,43(24):2977-2981.
-
3周官保,卢央芳,卢根杰,俞麒麟,高丽.中性粒细胞与淋巴细胞比值对胰腺癌非手术患者预后影响的探讨[J].中国卫生检验杂志,2023,33(20):2511-2515. 被引量：1
-
4何栋,樊万里,张树泽,赵斌,程志斌.术前血小板与淋巴细胞比值与胰腺导管腺癌患者预后关系的Meta分析[J].华西医学,2024,39(5):771-775.
-
5郑芸,李清茹.3种化学发光检测系统检测CA19-9的一致性评价[J].标记免疫分析与临床,2024,31(5):936-940.
-
6姚宁,刘念念,许新梅,晋俊.血清纤维蛋白原作为胰腺导管腺癌的诊断和预后生物标志物的价值[J].医药论坛杂志,2024,45(13):1399-1402.
-
7韩荣双,单梦琛,刘婷,田字彬,荆雪.PLR对于胰腺癌手术患者预后的相关性研究[J].临床医学进展,2021,11(11):5340-5347.
-
8刘娜.炎症生物标志物在预测胃癌预后中的作用[J].临床医学进展,2023,13(12):19890-19898.
-
9沙娜提·努尔兰,许新才.炎症环境在胃恶性肿瘤的预后分析[J].临床医学进展,2024,14(1):1336-1342.
-
1Hepatobiliary & Pancreatic Diseases International[J].Hepatobiliary & Pancreatic Diseases International,2019,18(3).
-
2Shui-Ying Lei.Meetings and Courses[J].Hepatobiliary & Pancreatic Diseases International,2019,18(3).
-
3Teruhisa Sakamoto,Hiroaki Saito,Masataka Amisaki,Naruo Tokuyasu,Soichiro Honjo,Yoshiyuki Fujiwara.Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19–9 level as a prognostic factor in patients with resected pancreatic cancer[J].Hepatobiliary & Pancreatic Diseases International,2019,18(3):278-284. 被引量：3
-
4Hepatobiliary & Pancreatic Diseases International[J].Hepatobiliary & Pancreatic Diseases International,2019,18(3).
-
5Yang LI,Rongxin CUI,Weisheng YAN,Demin XU.Long-term adaptive informative path planning for scalar field monitoring using cross-entropy optimization[J].Science China(Information Sciences),2019,62(5):26-28. 被引量：3
-
6伊默尔·B.弗洛雷斯,王志勇.解放普罗米修斯:为法哲学而奋斗(面对面法律教育)[J].中国法学教育研究,2014(3):77-97.
-
7本刊编辑部.摘要编写须知[J].节水灌溉,2019(6):91-91.
-
8NADAO KOHNO,SHISHIR K.DUBE,MIKHAIL ENTEL,S.H.M.FAKHRUDDIN,DIANA GREENSLADE,MARIE-DOMINIQUE LEROUX,JAMIE RHOME,NGUYEN BA THUY.RECENT PROGRESS IN STORM SURGE FORECASTING[J].Tropical Cyclone Research and Review,2018,7(2):128-139. 被引量：5
-
9Amanda Garcia,Keith W.Hipel,Amer Obeidi.Classifying Metarational Stabilities in Conflicts[J].Journal of Systems Science and Systems Engineering,2019,28(3):265-284.
-
10Peter Layer,Nataliya Kashirskaya,Natalya Gubergrits.Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency[J].World Journal of Gastroenterology,2019,25(20):2430-2441. 被引量：4
